Kalydeco is the only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutationOriginal Article
You may also like
Exploring 3D Printing for Solid Dosage Drugs
Control Strategies and Method Development for...
CPHI Milan 2024: Fill/Finish and Sustainability
CPHI Milan 2024: Industry Trends Impacting Oral Solid...
CPHI Milan 2024: Evolution of Coating Design
Improving the Sustainability of API Manufacturing with...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.